Dorr Robert T, Ertl Gregory, Levine Norman, Brooks Chris, Bangert Jerry L, Powell Marianne Broome, Humphrey Stuart, Alberts David S
Department of Medicine, Cancer Center Division, University of Arizona, Tucson, AZ, USA.
Arch Dermatol. 2004 Jul;140(7):827-35. doi: 10.1001/archderm.140.7.827.
Three phase 1 clinical trials of a superpotent melanotropic peptide, melanotan-1 (MT-1, or [Nle(4)-D-Phe(7)]alpha-melanocyte-stimulating hormone) were performed to demonstrate safety for MT-1 therapy combined with UV-B light or sunlight.
Open-label studies at 2 dose levels of MT-1 combined with small doses of UV-B to the neck or buttock or full sunlight to half of the back.
Dermatology clinics at the Arizona Health Sciences Center, Tucson.
The first study randomized 4 subjects to MT-1 (0.08 mg/kg per day subcutaneously) and 4 subjects to injections of isotonic sodium chloride (9%) solution for 10 days, followed by neck irradiation with 3 times the minimal erythema dose (MED) of UV-B light. In the next study (n = 12), the MT-1 dosage was increased to 0.16 mg/kg per day for 10 days, with UV-B radiation (0.25-0.75 MED) given to a buttock site for 5 days during (n = 7) or after (n = 5) MT-1 administration. A final study randomized 8 subjects to 3 to 5 days of sunlight to half of the back or to sunlight plus 0.16 mg/kg of MT-1 for 5 days per week for 4 weeks.
Tanning in the first study was achieved in 3 of 4 subjects receiving MT-1, and these subjects also had 47% fewer sunburn cells at the irradiated neck site. More skin sites darkened with the higher dose of MT-1 in the second study. In the third study, there was significantly enhanced tanning of the back in the MT-1 group, and this was maintained at least 3 weeks longer than the tanning in the sunlight-only controls, who required 50% more sun-exposure time for equivalent tanning.
There were no pathologic findings at any UV-B or sun-exposed sites in any subject. Toxic effects due to MT-1 were minor, consisting of nausea and transient facial flushing.
Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light.
开展一项关于超强促黑素肽——黑素otan-1(MT-1,即[Nle(4)-D-Phe(7)]α-黑素细胞刺激素)的三项1期临床试验,以证明MT-1疗法联合UV-B光或阳光照射的安全性。
在2个剂量水平下进行开放标签研究,将MT-1与小剂量UV-B照射颈部或臀部,或让背部一半接受全日照相结合。
图森市亚利桑那健康科学中心的皮肤科诊所。
第一项研究将4名受试者随机分为接受MT-1(每天皮下注射0.08mg/kg)组和4名接受等渗氯化钠(9%)溶液注射组,为期10天,随后对颈部进行3倍最小红斑量(MED)的UV-B光照射。在第二项研究中(n = 12),MT-1剂量增加至每天0.16mg/kg,为期10天,在MT-1给药期间(n = 7)或之后(n = 5),对臀部进行5天的UV-B辐射(0.25 - 0.75MED)。最后一项研究将8名受试者随机分为两组,一组让背部一半接受3至5天阳光照射,另一组让背部一半接受阳光照射加每周5天、为期4周、每天0.16mg/kg的MT-1注射。
在第一项研究中,4名接受MT-1的受试者中有3名实现了晒黑,且这些受试者在照射的颈部部位晒伤细胞减少了47%。在第二项研究中,更高剂量的MT-1使更多皮肤部位变黑。在第三项研究中,MT-1组背部的晒黑明显增强,且这种晒黑效果比仅接受阳光照射的对照组维持时间至少长3周,对照组达到同等晒黑效果所需的日照时间多50%。
任何受试者在任何UV-B或阳光照射部位均未发现病理改变。MT-1引起的毒性作用较小,包括恶心和短暂的面部潮红。
黑素otan-1可安全地与UV-B光或阳光联合使用,且在对光的晒黑反应中似乎具有协同作用。